Physician profile
Dennis Anciro
NPI 1689683658
$651.60
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.06 · 2022: $14.37 · 2023: $370 · 2024: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $278.68 | 2023-2024 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $62.91 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $62.71 | 2023-2024 | Mounjaro |
| Exact Sciences Corporation | $55.54 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $40.18 | 2024 | Yupelri |
| Glaxosmithkline, LLC. | $37.26 | 2024 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $36.17 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.96 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $17.06 | 2019 | |
| Amgen INC. | $15.98 | 2024 | Repatha, Otezla |
| Astellas Pharma US INC | $14.15 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Anciro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.